MULTI-LINK ACKNOWLEDGMENTS IN MULTI-LINK DEVICES

    公开(公告)号:US20210045095A1

    公开(公告)日:2021-02-11

    申请号:US17083203

    申请日:2020-10-28

    IPC分类号: H04W72/04 H04W76/15

    摘要: This disclosure describes systems, methods, and devices related to multi-link acknowledgments. A device may transmit a trigger frame to a station device (STA) multi-link device (MLD), wherein the trigger frame polls the STA MLD to announce presence on communication links. The device may identify a null data packet (NDP) from the STA MLD announcing its presence on a set of communication links. The device may establish the set of communication links with the STA MLD, wherein the STA MLD comprises a plurality of station devices (STAs). The device may allocate a plurality of tone-sets to the plurality of STAs within the STA MLD. The device may identify energy on the allocated tone-sets for each link that the STA MLD has presence on.

    ANTENNA CONFIGURATION PARAMETERS
    8.
    发明申请

    公开(公告)号:US20200212985A1

    公开(公告)日:2020-07-02

    申请号:US16817255

    申请日:2020-03-12

    IPC分类号: H04B7/06

    摘要: This disclosure describes systems, methods, and devices related to antenna configuration parameters. A device may determine one or more antennas having one or more phases. The device may determine a first delay associated with a first antenna of the one or more antennas. The device may determine a second delay associated with a second antenna of the one or more antennas. The device may cause to send a frame to a first station device using the first antenna, wherein the frame comprises a first indication of the delay associated with the first antenna and a second indication of the delay associated with the second antenna.

    Biomarkers for diagnosis and prognosis of lung cancer

    公开(公告)号:US10677800B2

    公开(公告)日:2020-06-09

    申请号:US15704828

    申请日:2017-09-14

    申请人: Feng Jiang

    发明人: Feng Jiang

    摘要: Provided herein are methods for non-invasively diagnosing and/or prognosing a lung cancer and for determining the efficacy of a therapeutic treatment regimen for the lung cancer. Expression levels of at least two small non-coding RNAs, for example, microRNAs and small nucleolar RNAs, are measured and used to calculate an area under the curve (AUC) that provides a probability of lung cancer in the subject. The smoking history of the subject and, if present, the size of pulmonary nodules may be incorporated into the calculation.